[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360343-105":59,"doc-detail-360343-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","neo-hyport-open-label-randomised-parallel-group-superiority-trial-protocol","NEO-HYPORT - Open label, randomised, parallel group superiority trial - Protocol","","NEO-HYPORT evaluates whether delivering radiotherapy before surgery improves outcomes for patients with breast carcinoma compared with the standard postoperative (adjuvant) approach. The protocol uses a randomised, controlled, parallel-group, open-label, single-centre superiority design. The primary endpoint is 3-year disease-free survival, with secondary randomisation testing two hypofractionated schedules (40 Gy/15 fractions over 3 weeks versus 26 Gy/5 fractions over 1 week) in both treatment settings. The study also targets wound-healing safety and efficacy evidence for ultra-hypofractionated neoadjuvant radiotherapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/neo-hyport-open-label-randomised-parallel-group-superiority-trial-protocol/360343/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/neo-hyport-open-label-randomised-parallel-group-superiority-trial-protocol/360343.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What treatment comparison does the NEO-HYPORT trial test?","Question",{"text":113,"@type":114},"It compares neoadjuvant radiotherapy delivered before surgery with adjuvant radiotherapy delivered after surgery. The trial also considers radiotherapy timing in conjunction with neoadjuvant chemotherapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What is the primary endpoint of the study?",{"text":118,"@type":114},"The primary endpoint is 3-year disease-free survival.",{"name":120,"@type":111,"acceptedAnswer":121},"Which hypofractionated radiotherapy schedules are evaluated as secondary randomisation?",{"text":122,"@type":114},"Two schedules are tested: 40 Gy in 15 fractions over 3 weeks versus 26 Gy in 5 fractions over 1 week.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360343,1790375559,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Chatterjee et al. Trials (2026) 27:408  \n[https://doi.org/10.1186/s13063-026-09642-2](https://doi.org/10.1186/s13063-026-09642-2)  \nTrials  \n STUDY PROTOCOL Open Access  \nNEO-HYPORT: does neoadjuvant  \nradiotherapy improve breast cancer outcomes? An open label, randomised, parallel group, superiority trial to compare the disease-free survival following neoadjuvant versus adjuvant hypofractionated radiotherapy in breast cancer (NEO-HYPORT)  \nSanjoy Chatterjee1* , Santam Chakraborty1, Rosina Ahmed2, Sanjit Kumar Agarwal2, Indu Arun3, Abhishek Sharma2, Shaurav Maulik1 and Shagun Mahajan2  \nAbstract  \nBackground In the setting of curative treatment of breast carcinoma, radiotherapy is usually administered after surgery (adjuvant radiotherapy) .  \nWe intend to evaluate the impact of delivering radiation therapy prior to surgical intervention in the treatment of these patients.  \nMethods The NEO-HYPORT trial is designed as a randomised, controlled, parallel group, open-label, single-centre, superiority trial comparing neoadjuvant and adjuvant radiotherapy after neoadjuvant chemotherapy. The primary endpoint is 3-year disease-free survival. A secondary randomisation will evaluate two hypofractionated radiotherapy schedules (40 Gy / 15 fractions / 3 weeks vs 26 Gy / 5 fractions / 1 week) in the two settings.  \nDiscussion Conventionally radiation therapy is delivered following surgery as adjuvant radiation therapy. The reasons for the same have been manifold including the hypothesis that surgical wound healing following radiation therapy may be delayed. Various biological arguments and outcomes from the utilisation of neoadjuvant radiation in other tumour sites suggest that neoadjuvant radiation may provide superior disease control as compared to adjuvant radiation therapy. Emerging evidence on wound healing safety following radiotherapy to the breast is also reported. The NEO-HYPORT trial will provide high-quality evidence about the efficacy of neoadjuvant radiotherapy and establish the safety of ultra hypofractionated radiotherapy in this setting.  \nKeywords Breast cancer, Hypofractionated radiotherapy, Neoadjuvant radiotherapy  \n*Correspondence:  \nSanjoy Chatterjee  \n[sanjoy.chatterjee@tmckolkata.com](sanjoy.chatterjee@tmckolkata.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nChatterjee et al. Trials (2026) 27:408  \nTrial schema  \nFigure 1 shows the trial schema.  \nIntroduction  \nBackground and rationale {6a}  \nBreast cancer is the most common cancer affecting humans globally with an estimated 2.3 million new cases being diagnosed worldwide annually [1]. Radiotherapy, locally targeted to the breast/chest wall and or regional lymph nodes, is a core component of multi-disciplinary management of breast cancer. Interestingly, EBCTCG meta-analyses have demonstrated that us","cbCaifeb24aQdWn9","https://ap.wps.com/l/cbCaifeb24aQdWn9","pdf",1617504,27,"English","# Introduction\n## Background and rationale\n# Review of status of research and development in the subject\n## Trial schema","[{\"question\":\"What treatment comparison does the NEO-HYPORT trial test?\",\"answer\":\"It compares neoadjuvant radiotherapy delivered before surgery with adjuvant radiotherapy delivered after surgery. The trial also considers radiotherapy timing in conjunction with neoadjuvant chemotherapy.\"},{\"question\":\"What is the primary endpoint of the study?\",\"answer\":\"The primary endpoint is 3-year disease-free survival.\"},{\"question\":\"Which hypofractionated radiotherapy schedules are evaluated as secondary randomisation?\",\"answer\":\"Two schedules are tested: 40 Gy in 15 fractions over 3 weeks versus 26 Gy in 5 fractions over 1 week.\"}]","NEO-HYPORT - Open label, randomised, parallel group superiority trial - Protocol | PDF",1790139718,68,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef150d98747f6e5c0f621d3e0770a73a.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87c652006385812d3168483f1f17eddf.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/349896b61b5cc326d608a7d88319fcb9.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f6afbc859e30fc2faaacec9d2ae9b3d.webp",980,1301]